{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:26:15Z","timestamp":1778520375675,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41401-025-01568-w","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:08:03Z","timestamp":1745993283000},"page":"2723-2733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TSG attenuated NAFLD and facilitated weight loss in HFD-fed mice via activating the RUNX1\/FGF21 signaling axis"],"prefix":"10.1038","volume":"46","author":[{"given":"Zhen-lin","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-fu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-nan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-li","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei S, Wang L, Evans PC, Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. 2024;29:103910.","journal-title":"Drug Discov Today"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstrom H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842\u201352.","journal-title":"J Hepatol"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"1568_CR4","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263\u201373.","journal-title":"JAMA"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1568_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: the growing challenge. Hepatology. 2023;77:323\u201338.","journal-title":"Hepatology"},{"key":"1568_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","volume":"3","author":"KH Flippo","year":"2021","unstructured":"Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab. 2021;3:309\u201317.","journal-title":"Nat Metab"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/a-1778-4159","volume":"54","author":"E Szczepanska","year":"2022","unstructured":"Szczepanska E, Gietka-Czernel M. FGF21: a novel regulator of glucose and lipid metabolism and whole-body energy balance. Horm Metab Res. 2022;54:203\u201311.","journal-title":"Horm Metab Res"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"FM Fisher","year":"2016","unstructured":"Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223\u201341.","journal-title":"Annu Rev Physiol"},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","volume":"41","author":"M Zarei","year":"2020","unstructured":"Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, Vazquez-Carrera M. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol Sci. 2020;41:199\u2013208.","journal-title":"Trends Pharmacol Sci."},{"key":"1568_CR11","doi-asserted-by":"publisher","DOI":"10.1242\/dev.148296","volume":"146","author":"R Mevel","year":"2019","unstructured":"Mevel R, Draper JE, Lie-A-Ling M, Kouskoff V, Lacaud G. RUNX transcription factors: orchestrators of development. Development. 2019;146:dev148296.","journal-title":"Development"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/cells8101277","volume":"8","author":"S Kaur","year":"2019","unstructured":"Kaur S, Rawal P, Siddiqui H, Rohilla S, Sharma S, Tripathi DM, et al. Increased expression of RUNX1 in liver correlates with NASH activity score in patients with non-alcoholic steatohepatitis (NASH). Cells. 2019;8:1277.","journal-title":"Cells"},{"key":"1568_CR13","doi-asserted-by":"publisher","first-page":"8489","DOI":"10.3390\/ijms22168489","volume":"22","author":"DM Tripathi","year":"2021","unstructured":"Tripathi DM, Rohilla S, Kaur I, Siddiqui H, Rawal P, Juneja P, et al. Immunonano-lipocarrier-mediated liver sinusoidal endothelial cell-specific RUNX1 inhibition impedes immune cell infiltration and hepatic inflammation in murine model of NASH. Int J Mol Sci. 2021;22:8489.","journal-title":"Int J Mol Sci"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.3390\/ijms22105239","volume":"22","author":"L Bertran","year":"2021","unstructured":"Bertran L, Pastor A, Portillo-Carrasquer M, Binetti J, Aguilar C, Mart\u00ednez S, et al. The potential protective role of RUNX1 in nonalcoholic fatty liver disease. Int J Mol Sci. 2021;22:5239.","journal-title":"Int J Mol Sci"},{"key":"1568_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112577","volume":"252","author":"L Lin","year":"2020","unstructured":"Lin L, Hao ZX, Zhang SB, Shi L, Lu B, Xu H, et al. Study on the protection of water extracts of Polygoni Multiflori Radix and Polygoni Multiflori Radix Praeparata against NAFLD and its mechanism. J Ethnopharmacol. 2020;252:112577.","journal-title":"J Ethnopharmacol"},{"key":"1568_CR16","first-page":"4958","volume":"14","author":"ZH Lou","year":"2017","unstructured":"Lou ZH, Xia BH, Su J, Yu JJ, Yan MQ, Huang YF, et al. Effect of a stilbene glycoside-rich extract from Polygoni Multiflori Radix on experimental non-alcoholic fatty liver disease based on principal component and orthogonal partial least squares discriminant analysis. Exp Ther Med. 2017;14:4958\u201366.","journal-title":"Exp Ther Med"},{"key":"1568_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/0973-1296.204563","volume":"13","author":"P Lin","year":"2017","unstructured":"Lin P, Lu JM, Wang YF, Gu W, Zhao RH, Yu J. Prevention mechanism of 2,3,5,4\u2019-tetrahydroxy-stilbene-2-o-beta-d-glucoside on lipid accumulation in steatosis hepatic L-02 cell. Pharmacogn Mag. 2017;13:245\u201353.","journal-title":"Pharmacogn Mag"},{"key":"1568_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.153994","volume":"99","author":"SB Zhang","year":"2022","unstructured":"Zhang SB, Wu ZQ, Shi L, Yan SH, Huang ZL, Lu B, et al. 2,3,5,4\u2019-tetrahydroxy-stilbene-2-o-beta-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5. Phytomedicine. 2022;99:153994.","journal-title":"Phytomedicine"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"1568_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne). 2020;11:601290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27:1262\u201371.","journal-title":"Nat Med"},{"key":"1568_CR22","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0904187106","volume":"106","author":"MJ Potthoff","year":"2009","unstructured":"Potthoff MJ, Inagaki T, Satapati S, Ding XS, He TT, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA. 2009;106:10853\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1568_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14384-z","volume":"11","author":"S Byun","year":"2020","unstructured":"Byun S, Seok S, Kim YC, Zhang Y, Yau P, Iwamori N, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun. 2020;11:807.","journal-title":"Nat Commun"},{"key":"1568_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1530\/EC-20-0152","volume":"9","author":"H Keinicke","year":"2020","unstructured":"Keinicke H, Sun G, Mentzel CMJ, Fredholm M, John LM, Andersen B, et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. Endocr Connect. 2020;9:755\u201368.","journal-title":"Endocr Connect"},{"key":"1568_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83075","volume":"12","author":"C Liu","year":"2023","unstructured":"Liu C, Sch\u00f6nke M, Spoorenberg B, Lambooij JM, van der Zande HJP, Zhou E, et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife. 2023;12:e83075.","journal-title":"Elife"},{"key":"1568_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","volume":"23","author":"C Schlein","year":"2016","unstructured":"Schlein C, Talukdar S, Heine M, Fischer AW, Krott LM, Nilsson SK, et al. FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab. 2016;23:441\u201353.","journal-title":"Cell Metab"},{"key":"1568_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2021.12.016","volume":"185","author":"A Sakers","year":"2022","unstructured":"Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185:419\u201346.","journal-title":"Cell"},{"key":"1568_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","volume":"17","author":"ZF Lin","year":"2013","unstructured":"Lin ZF, Tian HS, Lam KS, Lin SQ, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17:779\u201389.","journal-title":"Cell Metab"},{"key":"1568_CR29","doi-asserted-by":"publisher","first-page":"34533","DOI":"10.1074\/jbc.M111.248591","volume":"286","author":"X Ge","year":"2011","unstructured":"Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor\/Ets-like protein-1 in adipocytes. J Biol Chem. 2011;286:34533\u201341.","journal-title":"J Biol Chem"},{"key":"1568_CR30","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/ijms23052406","volume":"23","author":"Y Li","year":"2022","unstructured":"Li Y, Fromme T. Uncoupling protein 1 does not produce heat without activation. Int J Mol Sci. 2022;23:2406.","journal-title":"Int J Mol Sci"},{"key":"1568_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphys.2019.00037","volume":"10","author":"D Cuevas-Ramos","year":"2019","unstructured":"Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37.","journal-title":"Front Physiol"},{"key":"1568_CR32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jcsm.12409","volume":"10","author":"LJ Oost","year":"2019","unstructured":"Oost LJ, Kustermann M, Armani A, Blaauw B, Romanello V. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019;10:630\u201342.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1568_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115877","volume":"145","author":"HW Jung","year":"2021","unstructured":"Jung HW, Park JH, Kim DA, Jang IY, Park SJ, Lee JY, et al. Association between serum FGF21 level and sarcopenia in older adults. Bone. 2021;145:115877.","journal-title":"Bone"},{"key":"1568_CR34","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s11739-023-03339-z","volume":"18","author":"G Tarantino","year":"2023","unstructured":"Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Intern Emerg Med. 2023;18:1887\u201395.","journal-title":"Intern Emerg Med"},{"key":"1568_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.153994","volume":"101","author":"B Tucker","year":"2019","unstructured":"Tucker B, Li H, Long X, Rye KA, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019;101:153994.","journal-title":"Metabolism"},{"key":"1568_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","volume":"6","author":"FM Fisher","year":"2016","unstructured":"Fisher FM, Kim M, Doridot L, Cunniff JC, Parker TS, Levine DM, et al. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab. 2016;6:14\u201321.","journal-title":"Mol Metab"},{"key":"1568_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-981-10-3233-2_5","volume":"962","author":"C Bonifer","year":"2017","unstructured":"Bonifer C, Levantini E, Kouskoff V, Lacaud G. RUNX1 structure and function in blood cell development. Adv Exp Med Biol. 2017;962:65\u201381.","journal-title":"Adv Exp Med Biol"},{"key":"1568_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188715","volume":"1877","author":"TC Lin","year":"2022","unstructured":"Lin TC. RUNX1 and cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188715.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1568_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30570","volume":"125","author":"AM Woodworth","year":"2024","unstructured":"Woodworth AM, Hardy K, Taberlay PC, Dickinson JL, Holloway AF. RUNX1 regulates promoter activity in the absence of cognate DNA binding motifs. J Cell Biochem. 2024;125:e30570.","journal-title":"J Cell Biochem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01568-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:03:43Z","timestamp":1758751423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01568-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Li Jian is employed by Jinling Pharmaceutical Co., Ltd., but the study design, data analysis or writing of our manuscript were not affected by this company. All the authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}